Control of Chronic schistosomiasis sequelae

Estimates show that at least 206.5 million people still require preventive treatment against Chronic schistosomiasis and that the transmission still persist in 78 countries globally with more than 200,000 deaths attributable to the disease and associated tissue pathology annually.

Under a twelve months collaborative research project, ICGEB Cytokines and Disease Group led by F. Brombacher and the Merck Global Health Institute are investigating the ability of their compounds to ameliorate tissue pathology in experimental murine models of chronic schistosomiasis.

Duration: 2017-2018

Donor/funding programme:

Link to the ICGEB partner logo on the Merck Website